Physician

Peter Yz Jiang, MD, PHD

According to 2025 Medicare claims, Peter Jiang, MD, PHD (NPI: 1689614398) practices medical oncology in the Everett, WA market, with the plurality of this provider's patient population coming from Snohomish, WA. This provider's primary affiliated billing organization is OPTUM CARE WASHINGTON PLLC (NPI: 1831186766; TIN: 910214500) and primary practice location at 98201-1621. Jiang is affiliated with the PSW ACO (ACO ID: A5323) and CareMount Value Partners IPA (ACO ID: D0019), participating under both the MSSP and REACH models.

Jiang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 365 traditional Medicare patients, billed 64,036 HCPCS/CPT codes, and received $1,534,695 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,468 prescription claims across 288 beneficiaries totaling $5,029,323 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 157 claims. Open Payments data shows 1 records totaling $88. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $592,599 to $1,534,695. Similarly, Part D prescription costs have risen steadily, from $1,565,768 to $5,029,323. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $3,502 and ending at $8,499.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	428	30,889	$592,599
2016	399	100,074	$753,107
2017	374	45,336	$598,224
2018	395	50,719	$879,934
2019	448	61,253	$806,444
2020	349	33,941	$545,946
2021	407	53,168	$1,098,126
2022	363	54,467	$1,123,290
2023	405	88,126	$1,594,243
2024	365	64,036	$1,534,695

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	270	1,404	$1,565,768
2016	295	1,719	$1,574,524
2017	265	1,397	$1,825,887
2018	248	1,365	$2,377,792
2019	284	1,519	$3,166,674
2020	281	1,593	$3,514,415
2021	260	1,307	$2,330,271
2022	229	1,062	$1,956,997
2023	274	1,173	$2,298,629
2024	288	1,468	$5,029,323

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	122	$37,418
2016	N/R	18	$339
2017	N/R	66	$2,776
2018	N/R	13	$245
2019	N/R	41	$4,486
2020	N/R	163	$8,588
2021	N/R	51	$1,361
2022	N/R	N/R	N/R
2023	N/R	80	$5,118
2024	N/R	157	$9,251

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	92	185	$102
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	87	118	$80
80053	Blood test, comprehensive group of blood chemicals	81	260	$10
36415	Insertion of needle into vein for collection of blood sample	108	337	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	101	342	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	39	1,104	$1,088,992
Tagrisso	Osimertinib Mesylate	36	1,080	$743,444
Xtandi	Enzalutamide	47	1,410	$673,010
Calquence	Acalabrutinib Maleate	30	900	$316,243
Zejula	Niraparib Tosylate	15	450	$295,772

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0781	Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient	Y	N/R	21	$4,613
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	45	$1,923
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	40	$1,740
J9190	Injection, fluorouracil, 500 mg	N	N/R	51	$974

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$88	Regeneron Healthcare Solutions, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Peter Yz Jiang, MD, PHD?

Tedicare shows public-source Medicare data for Peter Yz Jiang, MD, PHD (NPI 1689614398), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Peter Yz Jiang, MD, PHD have ACO affiliation data?

Peter Yz Jiang, MD, PHD is shown with ACO affiliation data for PSW ACO (MSSP, ACO ID A5323) and CareMount Value Partners IPA (REACH, ACO ID D0019).

What billing organization is linked to Peter Yz Jiang, MD, PHD?

Peter Yz Jiang, MD, PHD is linked to OPTUM CARE WASHINGTON PLLC (billing NPI 1831186766) in the available physician profile data.

Does Peter Yz Jiang, MD, PHD have Open Payments data?

Peter Yz Jiang, MD, PHD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.